Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202502019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Mohammad Nasrullah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H1, Canada. Hauptthemen laut MEDLINE: RNA, Small Interfering, Nanoparticles, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myeloid-Lymphoid Leukemia Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mitacs, Edmonton Civic Employees Charitable Assistance Fund, CIHR.
Abstract (Originalsprache)
Effective siRNA delivery in acute lymphoblastic leukemia (ALL) is limited by preferential hepatic accumulation. To address this, a lipopolymer (PEI‐C) is developed by conjugating lipid to polyethylenimine and formulated lipopolymer nanoparticles (LPNPs) via complexation with siRNA. The siRNA delivery efficiency of LPNPs is evaluated in vitro in t(4;11)‐positive ALL cells (RS4;11 and SEM) as well as “normal” peripheral blood mononuclear cells (PBMCs) from human donors and bone marrow stromal cells (BMSCs) from mice. Molecular effects are assessed by quantifying target mRNA silencing and downstream apoptosis. In vivo biodistribution and therapeutic efficacy are examined in mouse models. LPNPs demonstrated significantly higher siRNA uptake than commercial reagents in PBMCs and BMSCs, reaching siRNA uptakes of 87.2% and 93.0% in RS4;11 and SEM cells, respectively. Molecular analyses revealed effective silencing of KMT2A::AFF1 mRNA (≈80% in RS4;11), accompanied by BCL2 downregulation and increased apoptosis. In vivo, LPNPs showed efficient siRNA biodistribution to leukemia‐associated organs (spleen and bone marrow) and significantly reduced leukemia burden in a systemic RS4;11 xenograft mouse model and improved survival. These findings suggest that PEI‐C‐formulated LPNPs present a promising avenue for therapeutic siRNA delivery in ALL, effectively targeting leukemia‐associated organs, and warrant further exploration in clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2H1, Canada.
- Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB, T6G 1R1, Canada.
- Department of Medical Genetics, Terry Fox Laboratory, British Columbia Cancer Research Institute, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
- Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, T6G 1Z2, Canada.
- Division of Hematology, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, T6G 2B7, Canada.
- Princess Maxima Center for Pediatric Oncology, Utrecht, CS, 3584, The Netherlands.
ORCID-Profile: Mohammad Nasrullah, Spencer B Gibson, Olaf Heidenreich, Hasan Uludağ
Förderung
- Mitacs
- Edmonton Civic Employees Charitable Assistance Fund
- CIHR
- Canadian Cancer Society
- Alex's Lemonade Stand Foundation
- Natural Sciences and Engineering Council of Canada
- Cancer Research Institute of Northern Alberta
- Canadian Institutes of Health Research
Zitieren
APA
Nasrullah, M., Kc, R., Rajendran, A. P., Dezfouli, S. A., Kucharski, C., Jiang, X., Gibson, S. B., Brandwein, J., Heidenreich, O., & Uludağ, H. (2025). Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202502019
Vancouver
Nasrullah M, Kc R, Rajendran AP, Dezfouli SA, Kucharski C, Jiang X, et al. Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202502019
BibTeX
@article{Nasrullah2025,
author = {Nasrullah, Mohammad and Kc, Remant and Rajendran, Amarnath Praphakar and Dezfouli, Saba Abbasi and Kucharski, Cezary and Jiang, Xiaoyan and Gibson, Spencer B and Brandwein, Joseph and Heidenreich, Olaf and Uludağ, Hasan},
title = {Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202502019}
}
EUVIMED